D
Dariusz M. Kowalski
Researcher at Curie Institute
Publications - 161
Citations - 12935
Dariusz M. Kowalski is an academic researcher from Curie Institute. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 25, co-authored 129 publications receiving 7930 citations.
Papers
More filters
Journal ArticleDOI
A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors
Lecia V. Sequist,Ji-Youn Han,Myung-Ju Ahn,Byoung Chul Cho,Helena A. Yu,Sang-We Kim,James Chih-Hsin Yang,Jong-Seok Lee,Wu Chou Su,Dariusz M. Kowalski,S. M. Orlov,Mireille Cantarini,Remy B. Verheijen,Anders Mellemgaard,Paul Frewer,Xiaoling Ou,Geoffrey R. Oxnard +16 more
TL;DR: The TATTON study as mentioned in this paper showed that the combination of osimertinib and osimetricinib may overcome MET-driven resistance to EGFR-TKIs in non-small cell lung cancer.
Journal ArticleDOI
Thoracic neoplasms
Maciej Krzakowski,Jacek Jassem,Adam Antczak,Katarzyna Błasińska,Joanna Chorostowska-Wynimko,Rafal Dziadziuszko,Maciej Glogowski,Tomasz Grodzki,Dariusz M. Kowalski,Rafał Krenke,Renata Langfort,Włodzimierz Olszewski,Tadeusz Orłowski,Pawel Sliwinski,Andrzej Tysarowski,Witold Rzyman,Marek Woźniewski +16 more
Journal ArticleDOI
Management of nivolumab-induced pulmonary toxicity — pneumonitis
TL;DR: In severe cases, hospitalisation is necessary and other forms of immunosuppression (infliximab, mycophenolate mofetil) may be considered.
Journal ArticleDOI
Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC
W. Schütte,Fabrice Barlesi,Kwan Park,Fortunato Ciardiello,J. von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,M Cobo Dols,Diego Cortinovis,Joseph W. Leach,J Polikoff,Gandara, DR[Gandara, D. R.],Carlos H. Barrios,Daniel S. Chen,Pei He,Marcus Ballinger,Daniel Waterkamp,Alan Sandler,Achim Rittmeyer +19 more
Journal Article
OAK, a randomized Ph III study of atezolizumab vs docetaxel in patients with advanced NSCLC: results from subgroup analyses
W. Schütte,S. Gadgeel,Fortunato Ciardiello,Achim Rittmeyer,Fabrice Barlesi,Diego Cortinovis,Carlos H. Barrios,Toyoaki Hida,K. Park,Dariusz M. Kowalski,Manuel Cobo Dols,Joseph W. Leach,Jonathan Polikoff,C. Matheny,Pei He,Marcin Kowanetz,Daniel S. Chen,Daniel Waterkamp,Marcus Ballinger,Alan Sandler,Gandara, DR[Gandara, D. R.],Jmd von Pawel +21 more